The Role of Big Pharma in Orphan Drug Development and Commercialization

In Partnering & Investment by Cameron

Orphan drug development is often perceived as being done by small biotech companies. However, most big pharmaceutical companies are heavily invested in the rare disease community.

In this exclusive interview with Rare Disease Report, Bert Bruce, Vice President of Rare Disease Commercial Development at Pfizer Inc, previews his presentation at the upcoming World Orphan Drug Congress USA 2014 being held in Washington D.C., April 23-25th. The presentation will focus in the important role big pharma plays in the rare disease community.